Temozolomide chemotherapy versus radiotherapy in high-risk low-grade glioma: A randomized phase III Intergroup study by EORTC/NCIC-CTG/TROG/MRC-CTU (EORTC 22033-26033)

BACKGROUND: Outcome of low-grade glioma (LGG, WHO grade II) is highly variable reflecting molecular heterogeneity of the disease. We compared two different single modality treatment strategies: standard radiotherapy (RT) versus primary temozolomide (TMZ) chemotherapy with the aim of tailoring treatm...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Lancet Oncol
Autors principals: Baumert, Brigitta G., Hegi, Monika E., van den Bent, Martin J., von Deimling, Andreas, Gorlia, Thierry, Hoang-Xuan, Khê, Brandes, Alba A., Kantor, Guy, Taphoorn, Martin J.B., Hassel, Mohamed Ben, Hartmann, Christian, Ryan, Gail, Capper, David, Kros, Johan M., Kurscheid, Sebastian, Wick, Wolfgang, Enting, Roelien, Reni, Michele, Thiessen, Brian, Dhermain, Frederic, Bromberg, Jacoline E., Feuvret, Loic, Reijneveld, Jaap C., Chinot, Olivier, Gijtenbeek, Johanna M. M., Rossiter, John P., Dif, Nicolas, Balana, Carmen, Bravo-Marques, Jose, Clement, Paul M., Marosi, Christine, Tzuk-Shina, Tzahala, Nordal, Robert A., Rees, Jeremy, Lacombe, Denis, Mason, Warren P., Stupp, Roger
Format: Artigo
Idioma:Inglês
Publicat: 2016
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC5124485/
https://ncbi.nlm.nih.gov/pubmed/27686946
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/S1470-2045(16)30313-8
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars